• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    PEAK ROCK CAPITAL AFFILIATE SELLS PARAGON HEALTHCARE, INC. TO ELEVANCE HEALTH

    1/5/24 8:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care
    Get the next $ELV alert in real time by email

    Paragon doubles revenues and increases the number of infusion centers by 400% during Peak Rock's ownership

    AUSTIN, Texas, Jan. 5, 2024 /PRNewswire/ -- An affiliate of Peak Rock Capital ("Peak Rock"), a leading middle-market private investment firm, announced today it has signed a definitive agreement for the sale of Paragon Healthcare, Inc. ("Paragon" or the "Company") to Elevance Health (NYSE:ELV).

    Paragon is a leading provider of ambulatory and home infusion services as well as specialty pharmacy services. The Company provides comprehensive, high quality infusion services to patients with chronic health conditions and those in need of post-acute care. Headquartered in Plano, Texas, with more than 70 infusion and pharmacy locations in 12 states, the Company has built an excellent reputation in the industry for its service to patients across lower-cost settings of care, including infusion centers and patients' homes.

    Since acquiring Paragon from its founders, Peak Rock supported the Company's strategic growth and operational initiatives. This included a significant expansion of the Company's ambulatory infusion center and pharmacy footprint, creating hundreds of jobs and expanding access to infusion care across multiple states. The Company also invested heavily in additional corporate infrastructure, including new team members, information technology systems, and enhanced operational capabilities. Paragon more than doubled revenue and increased the number of infusion centers by more than 400% during Peak Rock's ownership.

    Spencer Moore, Managing Director of Peak Rock, said, "Working with the team at Paragon has been a tremendous experience.  By supporting the Company with strategic and operational resources, Paragon has substantially grown its infusion footprint, patient-treatment capabilities, and organizational talent. These investments have enabled the business to support a rapidly growing patient-base, while helping to lower the cost of healthcare."

    Anthony Mollica, Chief Executive Officer of Paragon, added, "Peak Rock has been an invaluable partner to Paragon and has played a critical role in supporting our ambitious growth plans through investments in the Company's capabilities and people. We are excited to join Elevance Health and look forward to continuing to support our patients with high quality infusion care. In particular, I would like to thank the entire Paragon organization, without whom we could not have achieved our success to date."

    Anthony DiSimone, Chief Executive Officer of Peak Rock, said, "This transaction is another great example of Peak Rock's expertise in providing resources and strategic guidance to support the rapid growth and development of family and founder-owned businesses. We look forward to partnering with additional leading healthcare businesses that can benefit from Peak Rock's capabilities to achieve transformational outcomes."

    Jefferies LLC acted as the financial advisor and Kirkland & Ellis LLP acted as the legal advisor to the Company on the transaction.

    ABOUT PARAGON HEALTHCARE, INC.

    Founded in 2002, Paragon Healthcare, Inc. is a leading provider of infusion services to patients through its network of ambulatory infusion centers, home infusion pharmacies, and other specialty pharmacy services. The Company provides high quality, convenient, comfortable, and lower cost care to patients with chronic and acute conditions. Paragon is based in Plano, Texas. For more information visit www.paragonhealthcare.com.

    ABOUT PEAK ROCK CAPITAL

    Peak Rock Capital is a leading middle-market private investment firm that makes equity and debt investments in companies in North America and Europe. Peak Rock's equity investment platform focuses on opportunities where it can support senior management to drive rapid growth and performance improvement, with expertise in corporate carve-outs and partnering with families and founders seeking first-time institutional capital. Peak Rock's credit platform invests across capital structures, with a broad mandate to provide flexible, tailored capital solutions to middle-market and growth-oriented businesses. Peak Rock's real estate platform makes equity and debt investments in small to mid-sized real estate assets in attractive, growing geographies. For further information about Peak Rock Capital, please visit www.peakrockcapital.com

    Media Contact:

    Daniel Yunger

    Kekst CNC

    (212) 521-4800

    daniel.yunger@kekstcnc.com

     

    Cision View original content:https://www.prnewswire.com/news-releases/peak-rock-capital-affiliate-sells-paragon-healthcare-inc-to-elevance-health-302026739.html

    SOURCE Peak Rock Capital LLC

    Get the next $ELV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELV

    DatePrice TargetRatingAnalyst
    5/20/2026$498.00Hold → Buy
    Deutsche Bank
    4/29/2026$435.00Neutral → Buy
    BofA Securities
    4/8/2026$345.00In-line
    Evercore ISI
    2/3/2026$358.00Outperform → Sector Perform
    RBC Capital Mkts
    1/8/2026$425.00Peer Perform → Outperform
    Wolfe Research
    12/19/2025$320.00Buy → Hold
    Deutsche Bank
    10/14/2025Neutral
    Goldman
    7/21/2025Buy → Hold
    Argus
    More analyst ratings

    $ELV
    SEC Filings

    View All

    SEC Form 11-K filed by Elevance Health Inc.

    11-K - Elevance Health, Inc. (0001156039) (Filer)

    6/17/26 1:58:21 PM ET
    $ELV
    Medical Specialities
    Health Care

    SEC Form 11-K filed by Elevance Health Inc.

    11-K - Elevance Health, Inc. (0001156039) (Filer)

    6/17/26 1:57:10 PM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Elevance Health, Inc. (0001156039) (Filer)

    6/10/26 6:01:35 AM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    New Elevance Health Public Policy Institute Study Examines Payment Disputes for Planned Procedures Under the No Surprises Act

    Research finds arbitration awards for certain planned procedures are often far higher than typical in-network payment rates The No Surprises Act was created to protect patients from unexpected medical bills. While those patient protections are working, new research from the Elevance Health Public Policy Institute suggests that the law's payment dispute process is producing unexpected results for some planned medical procedures. The findings come as federal IDR volume has grown far beyond initial projections, raising concerns that a process intended as a limited payment-dispute backstop is increasingly contributing to higher out-of-network costs. The study examined more than 7,300 paym

    6/25/26 9:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    Thomas Carr Howe Middle School Unveils New Fitness and Strength Training Space Through Partnership with Elevance Health and Impact Fitness Foundation

    Thomas Carr Howe Middle School today celebrated the unveiling of a newly transformed fitness and strength training space made possible through a partnership with Elevance Health and the Impact Fitness Foundation (IFF). The project marks the fifth consecutive year that Elevance Health and IFF have invested in Indianapolis schools through community fitness initiatives connected to the Elevance Health Women’s Fort Myers Tipoff, a premier collegiate basketball tournament that celebrates the impact of women in sports. More than 40 Elevance Health volunteers worked alongside representatives from the Impact Fitness Foundation to renovate the school’s fitness and athletic training areas, creati

    6/24/26 3:00:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Makes Clinical Review Faster, More Connected with Health OS

    Elevance Health today announced advancements in how it helps streamline clinical review and create a simpler, faster, and more connected experience for care providers and members through Health OS. Health OS is Elevance Health’s secure data platform designed to connect health information across electronic health records (EHRs), labs, and health information exchanges, helping support more informed and timely clinical decisions while reducing administrative burden for care providers. By connecting with healthcare data systems, including Epic’s Payer Platform, Health OS helps reduce manual steps and deliver clearer clinical insights. "Health OS represents a foundational shift in how we app

    6/23/26 8:15:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Collis Steven H bought $869,520 worth of shares (3,000 units at $289.84), increasing direct ownership by 469% to 3,639 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    3/6/26 8:03:27 AM ET
    $ELV
    Medical Specialities
    Health Care

    Director Devore Susan D. bought $374,580 worth of shares (1,200 units at $312.15), increasing direct ownership by 52% to 3,502 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    8/21/25 4:20:38 PM ET
    $ELV
    Medical Specialities
    Health Care

    President and CEO Boudreaux Gail bought $2,438,951 worth of shares (8,500 units at $286.94), increasing direct ownership by 6% to 151,020 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    7/18/25 1:42:51 PM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Elevance Health upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded Elevance Health from Hold to Buy and set a new price target of $498.00

    5/20/26 8:03:29 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health upgraded by BofA Securities with a new price target

    BofA Securities upgraded Elevance Health from Neutral to Buy and set a new price target of $435.00

    4/29/26 8:00:15 AM ET
    $ELV
    Medical Specialities
    Health Care

    Evercore ISI initiated coverage on Elevance Health with a new price target

    Evercore ISI initiated coverage of Elevance Health with a rating of In-line and set a new price target of $345.00

    4/8/26 8:36:16 AM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CAO & Controller Penczek Ronald W sold $148,766 worth of shares (369 units at $403.16), decreasing direct ownership by 9% to 3,740 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    6/15/26 4:10:45 PM ET
    $ELV
    Medical Specialities
    Health Care

    Director Dixon Robert L Jr sold $60,667 worth of shares (151 units at $401.77), decreasing direct ownership by 1% to 10,734 units (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    6/12/26 4:12:50 PM ET
    $ELV
    Medical Specialities
    Health Care

    CAO & Controller Penczek Ronald W exercised 1,531 shares at a strike of $294.30 and sold $617,192 worth of shares (1,531 units at $403.13) (SEC Form 4)

    4 - Elevance Health, Inc. (0001156039) (Issuer)

    5/20/26 4:11:33 PM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Financials

    Live finance-specific insights

    View All

    Elevance Health Reports First Quarter 2026 Results; Raises Full-Year Guidance

    1Q 2026 operating revenue of $49.5 billion, up 1.5% from 1Q 2025 1Q 2026 diluted EPS1 of $8.00; adjusted diluted EPS2 of $12.58 driven by strong operating results and ~$1 per share of non-recurring investment income FY 2026 diluted EPS1 guidance to be at least $19.85, including the Company's estimate of the financial impact for the CMS matter FY 2026 adjusted diluted EPS2 guidance raised to at least $26.75, supported by underlying business strength, actions to reduce medical costs, and increased visibility Reaffirm FY 2026 operating cash flow of at least $5.5 billion, inclusive of potential cash payments for the CMS matter Returned $1.5 billion of capital to shareholders in

    4/22/26 6:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health to Hold Conference Call and Webcast to Discuss First Quarter 2026 Results on April 22, 2026

    Elevance Health (NYSE:ELV) will release first quarter 2026 financial results on April 22, 2026, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 - Access Code - 3972058 (Domestic) 312-470-0178 - Access Code - 3972058 (International) 800-391-9853 - No Access Code (Domestic Replay) 203-369-3269 - No Access Code (International Replay) The call will be available through a live webcast at www.elevancehealth.com under the "Investors" link. You may also acces

    3/30/26 4:30:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Reports Fourth Quarter and Full Year 2025 Results; Sets Full Year 2026 Outlook

    4Q 2025 operating revenue of $49.3 billion; FY 2025 of $197.6 billion 4Q 2025 diluted EPS1 of $2.47; adjusted diluted EPS2 of $3.33 FY 2025 diluted EPS1 of $25.21; adjusted diluted EPS2 of $30.29 Projected FY 2026 GAAP diluted EPS1 to be at least $22.30 Projected FY 2026 adjusted diluted EPS2 to be at least $25.50 Returned $4.1 billion of capital to shareholders in 2025 Reaffirming long-term earnings algorithm; recalibrating segment margin targets Elevance Health, Inc. (NYSE:ELV) reported fourth quarter and full year 2025 results. "Elevance Health delivered fourth quarter results in line with our outlook, reflecting disciplined execution in a dynamic environment. As

    1/28/26 6:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Elevance Health Inc.

    SC 13G/A - Elevance Health, Inc. (0001156039) (Subject)

    11/14/24 1:22:35 PM ET
    $ELV
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Elevance Health Inc.

    SC 13G - Elevance Health, Inc. (0001156039) (Subject)

    2/14/24 10:02:59 AM ET
    $ELV
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Elevance Health Inc.

    SC 13G - Elevance Health, Inc. (0001156039) (Subject)

    2/14/23 12:37:59 PM ET
    $ELV
    Medical Specialities
    Health Care

    $ELV
    Leadership Updates

    Live Leadership Updates

    View All

    Elevance Health Announces Management Changes; CFO Mark Kaye to Expand Responsibilities to Include Carelon and Felicia Norwood to Lead Consolidated Health Benefits Organization

    Elevance Health, Inc. (NYSE:ELV) today announced management changes designed to simplify decision-making and strengthen execution across Carelon and Health Benefits. As part of these changes, Mark Kaye, Executive Vice President and Chief Financial Officer, will expand his responsibilities to include oversight of Carelon, the Company's healthcare services operations including pharmacy services, behavioral health, value-based care, and care delivery capabilities. Carelon plays a critical role in advancing the Company's strategy to lower the cost of care. Carelon's operating priorities and client commitments remain unchanged. Felicia Norwood, Executive Vice President and Chief Health Benef

    2/26/26 3:02:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Board Welcomes Amy Schulman as New Director, Reflecting Ongoing Commitment to Governance Excellence

    The board of directors of Elevance Health (NYSE:ELV) today announced the appointment of Amy Schulman, a recognized healthcare executive, investor, and governance leader, as an independent director, effective January 12, 2026. Schulman will serve on the Audit and Finance Committees, contributing deep expertise in healthcare innovation, regulatory strategy, and value creation across complex, global enterprises. This appointment reflects Elevance Health's ongoing board refreshment strategy to ensure diverse, independent, and future-focused leadership that aligns with the company's long-term strategy and stakeholders' priorities. "Amy's record of driving innovation, disciplined investment, an

    12/10/25 4:30:00 PM ET
    $ELV
    Medical Specialities
    Health Care

    Elevance Health Appoints Nathan Rich Vice President, Investor Relations

    Elevance Health (NYSE:ELV) announced today the appointment of Nathan Rich as Vice President, Investor Relations, effective November 11, 2024. In this role, Mr. Rich will lead Elevance Health's investor relations efforts, providing strategic leadership to support the company's growth initiatives and strengthen relationships within the investment community. He will also serve as a member of the company's executive leadership team and will report directly to Mark Kaye, Executive Vice President and Chief Financial Officer. Mr. Rich succeeds Stephen Tanal, who now serves as Chief Financial Officer for Elevance Health's Government Health Benefits business. "Nate brings nearly two decades of expe

    11/4/24 9:00:00 AM ET
    $ELV
    Medical Specialities
    Health Care